RxDoctor Payments Data

John Bundy, MD

Family Medicine · Yukon, OKNPI 1821027210

Payments from drug & device makers

$10,224in general payments, 2019–2025

Across 716 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$950
  • AstraZeneca$934
  • Boehringer Ingelheim$775
  • GSK$713
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$10,01298%
  • Education$2122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,224 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$132,694
Medicare patients
369
Services billed
1,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$85,953
EliquisApixaban54$50,205
JanuviaSitagliptin Phosphate33$40,490
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$19,414
XareltoRivaroxaban31$17,075
MyrbetriqMirabegron20$16,420
MounjaroTirzepatide14$14,095
Montelukast Sodium415$6,866
Risedronate Sodium46$6,405
Rosuvastatin Calcium307$5,443
Levothyroxine Sodium502$5,363
Atorvastatin Calcium399$5,349
Valsartan97$3,505
Dexlansoprazole DrDexlansoprazole23$3,214
Pantoprazole Sodium211$2,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$775$85,95376 claims
PfizerEliquis$1,219$50,20554 claims
MerckJanuvia$147$40,49033 claims
GSKTrelegy Ellipta$713$19,41431 claims
Johnson & JohnsonXarelto$107$17,07531 claims
Astellas Pharma US IncMyrbetriq$705$16,42020 claims
Lilly USA, LLCMounjaro$1,164$14,09514 claims
AbbVieSynthroid$594$2,75435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →